Defendant
1 case as defendant.
Senseonics Holdings, Inc. (NASDAQ: SENS) is a medical technology company headquartered in Germantown, Maryland, founded in 1996. The company became publicly held, listing on the NYSE American and later on NASDAQ. As of June 11, 2026, Senseonics had a market capitalization of approximately $383 million and reported a trailing 12-month revenue of $40.7 million as of March 31, 2026. It employs approximately 130 individuals.
Senseonics specializes in the development and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes. Its flagship product is the Eversense CGM System, which includes an under-the-skin sensor, a removable and rechargeable smart transmitter worn over the sensor, and a mobile application for real-time glucose monitoring. The product line includes Eversense E3, which offers 180-day sensor longevity, and Eversense 365, providing year-long glucose monitoring.
In terms of patent litigation, Senseonics Holdings, Inc. operates as an operating company that defends against patent infringement claims. The company has been named as a defendant in one tracked case and has not initiated any patent suits as a plaintiff. Its single tracked case, Cellspin Soft, Inc. v. Senseonics Holdings, Inc., was filed in the Eastern District of Texas, a venue known to be favorable to patent plaintiffs.
A patent infringement lawsuit filed by Cellspin Soft, Inc. against Senseonics Holdings, Inc. et al. in the Texas Eastern District Court, asserting US patent 8904030, which is currently open.